Regeneron Pharma Q2 Results Top Estimates - Update

RTTNews | 195 days ago
Regeneron Pharma Q2 Results Top Estimates - Update

(RTTNews) - Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.35 billion or $11.56 per share, compared to $1.18 billion or $10.24 per share in the year-ago quarter.

On average, 23 analysts polled by Thomson Reuters expected the company to report earnings of $10.61 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter grew 12 percent to $3.55 billion from $3.16 billion in the same quarter last year. Analysts were looking for revenues of $3.38 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | 229 days ago
Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews | 376 days ago
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 957 days ago
India Inflation Weakens More Than Forecast To Lowest Level In 5 Months

India Inflation Weakens More Than Forecast To Lowest Level In 5 Months

India's consumer price inflation slowed more than expected to a five-month low in January reinforcing expectations that the Reserve Bank of India will reduce interest rates further. The consumer price index registered an increase of 4.31 percent on a yearly basis in January, weaker than the 5.22 percent rise logged in December, official data revealed on Wednesday.
RTTNews | 6h 20min ago
Bay Street Likely To Open On Weak Note

Bay Street Likely To Open On Weak Note

Lower crude oil and bullion prices point to a negative start for the Canadian market Wednesday morning. U.S. consumer price inflation data is likely to make a significant impact on price movements.
RTTNews | 6h 53min ago
FTSE 100 Flat In Lackluster Trade; Barratt Redrow Rises On Strong Earnings

FTSE 100 Flat In Lackluster Trade; Barratt Redrow Rises On Strong Earnings

U.K. stocks are moving in a tight band along the flat line Wednesday morning as investors largely stay cautious ahead of U.S. consumer price inflation data due later in the day. Fears of a global trade war following fresh tariffs by the Trump administration weigh on sentiment.
RTTNews | 7h 52min ago